BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, Grayson PC, McAdoo SP, Mason JC, Owen C, Weyand CM, Youngstein T, Dhaun N. Large-vessel vasculitis. Nat Rev Dis Primers 2022;7:93. [PMID: 34992251 DOI: 10.1038/s41572-021-00327-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Tarkin JM, Gopalan D. Multimodality imaging of large-vessel vasculitis. Heart 2022. [DOI: 10.1136/heartjnl-2022-321113] [Reference Citation Analysis]
2 Aymonnier K, Amsler J, Lamprecht P, Salama A, Witko‐sarsat V. The neutrophil: A key resourceful agent in immune‐mediated vasculitis. Immunological Reviews 2022. [DOI: 10.1111/imr.13170] [Reference Citation Analysis]
3 Michailidou D, Zhang T, Kuderer NM, Lyman GH, Diamantopoulos AP, Stamatis P, Ng B. Predictive models for thromboembolic events in giant cell arteritis: A US veterans health administration population-based study. Front Immunol 2022;13:997347. [DOI: 10.3389/fimmu.2022.997347] [Reference Citation Analysis]
4 Henes JC, Saur S. Diagnostik und Therapie der Großgefäßvaskulitiden – Wo stehen wir aktuell? Aktuelle Rheumatologie 2022. [DOI: 10.1055/a-1931-3989] [Reference Citation Analysis]
5 Misra DP, Jain N, Ora M, Singh K, Agarwal V, Sharma A. Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis. Diagnostics (Basel) 2022;12:2565. [PMID: 36292253 DOI: 10.3390/diagnostics12102565] [Reference Citation Analysis]
6 Kiefer J, Mazzeffi M. Complications of Vascular Disease. Anesthesiology Clinics 2022. [DOI: 10.1016/j.anclin.2022.08.006] [Reference Citation Analysis]
7 Misra DP, Rathore U, Kopp CR, Patro P, Agarwal V, Sharma A. Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol 2022. [PMID: 35927524 DOI: 10.1007/s10067-022-06318-5] [Reference Citation Analysis]
8 Rizzo C, La Barbera L, Miceli G, Tuttolomondo A, Guggino G. The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease. Front Mol Med 2022;2. [DOI: 10.3389/fmmed.2022.933161] [Reference Citation Analysis]
9 Grän F, Schilling B. Kutane Nebenwirkungen unter Immun-Checkpoint-Inhibitor-Therapie. Aktuelle Rheumatologie 2022;47:344-352. [DOI: 10.1055/a-1794-9687] [Reference Citation Analysis]
10 Shi H, Wu H, Winkler MA, Belin de Chantemèle EJ, Lee R, Kim HW, Weintraub NL. Perivascular adipose tissue in autoimmune rheumatic diseases. Pharmacol Res 2022;182:106354. [PMID: 35842184 DOI: 10.1016/j.phrs.2022.106354] [Reference Citation Analysis]
11 Watanabe R, Hashimoto M. Perspectives of JAK Inhibitors for Large Vessel Vasculitis. Front Immunol 2022;13:881705. [PMID: 35432355 DOI: 10.3389/fimmu.2022.881705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Samson M, Bonnotte B. Comment appliquer les recommandations EULAR et ACR pour le diagnostic et le traitement de l’artérite à cellules géantes ? La Revue de Médecine Interne 2022. [DOI: 10.1016/j.revmed.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]